Medtronic Expands Diabetes Portfolio with Medicare Access and FDA Clearances
Event summary
- Medtronic gained Medicare access for the MiniMed™ 780G system paired with Abbott's Instinct sensor.
- FDA cleared the MiniMed™ 780G system for use with ultra rapid-acting insulins Fiasp and Lyumjev.
- FDA cleared the MiniMed™ 780G system for use with the Instinct sensor for insulin-requiring type 2 diabetes.
- Medtronic aims to expand access and choice for people living with type 1 and insulin-requiring type 2 diabetes.
The big picture
Medtronic's latest milestones reflect a strategic push to dominate the automated insulin delivery market. By expanding sensor and insulin options, the company aims to capture a larger share of the type 1 and insulin-requiring type 2 diabetes segments. The Medicare access and FDA clearances position Medtronic to compete more effectively in a rapidly evolving healthcare technology landscape.
What we're watching
- Market Penetration
- How the Medicare access will drive adoption of the MiniMed™ 780G system among older patients.
- Competitive Dynamics
- Whether Medtronic can sustain its market position against competitors like Dexcom and Insulet.
- Regulatory Compliance
- The pace at which Medtronic can secure additional FDA clearances for new insulin and sensor combinations.